• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Interferon alfa and antiretroviral agents: a treatment option for adult T-cell leukemia/lymphoma.
【24h】

Interferon alfa and antiretroviral agents: a treatment option for adult T-cell leukemia/lymphoma.

机译：干扰素α和抗逆转录病毒药物：成人T细胞白血病/淋巴瘤的治疗选择。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy caused by human T-cell lymphotropic virus type I, and its clinical subtypes are categorized into smoldering, chronic, lymphoma and acute types. The standard care for patients with the acute, lymphoma and unfavorable chronic types (aggressive ATL) consists of intensive chemotherapy with or without subsequent allogeneic hematopoietic stem cell transplant, or a combination of interferon alfa and an antiretroviral agent, while that for the chronic type without unfavorable prognostic factors and the smoldering type (indolent ATL) is watchful waiting. Recently, early intervention for indolent ATL employing interferon alfa and an antiretroviral agent has been reported to lead to a marked benefit in a retrospective study. This modality should be evaluated in larger clinical trials, since patients with indolent ATL show a median survival time of as short as 4-5 years.
机译：成人T细胞白血病/淋巴瘤（ATL）是由人I型T细胞淋巴病毒引起的周围性T细胞恶性肿瘤，其临床亚型分为闷热，慢性，淋巴瘤和急性类型。对于患有急性，淋巴瘤和不利的慢性类型（侵略性ATL）的患者，标准治疗包括加重化疗，有或没有随后的同种异体造血干细胞移植，或干扰素α和抗逆转录病毒药物的联合治疗;而对于慢性型则无不利的预后因素和阴燃类型（惰性ATL）正在等待观察。最近，在一项回顾性研究中，已经报道了采用干扰素α和一种抗逆转录病毒药物对惰性ATL进行早期干预的显着益处。这种方式应在较大的临床试验中进行评估，因为惰性ATL患者的中位生存期可短至4-5年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号